Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes

Antiviral Research

Volumn 54, Issue 3, 2002, Pages 175-188

  De Mareuil, Jean ^a   Mabrouk, Kamel ^a   Doria, Evelyne ^a   Moulard, Maxime ^b   De Chasteigner, Stéphanie ^c   Oughideni, Razika ^a   Van Rietschoten, Jurphaas ^a   Rochat, Hervé ^a   De Waard, Michel ^d   Sabatier, Jean Marc ^a  

^a CNRS   (France)

^b Biocytex   (France)

^c Cellpep S A   (France)

^d INSERM   (France)

Author keywords

Antiviral; HIV; Liposome; Lymphocyte; SPC3

Indexed keywords

ANTIVIRUS AGENT; CHOLESTEROL; LIPOSOME; SPC 3; SPC 3 LIPOSOME CONJUGATE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENCAPSULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; MOLECULAR SIZE; PRIORITY JOURNAL; SYNCYTIUM; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; GIANT CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LIPOSOMES; LYMPHOCYTES; RECOMBINANT PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036223804     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00002-5     Document Type: Article

References (47)

1. Liposome disposition in vivo. III. Dose and vesicle-size effects
2. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
3. Pharmacokinetics of stealth versus conventional liposomes: Effect of dose
4. Uptake of liposomes by cultured mouse bone marrow macrophages: Influence of liposome composition and size
5. Subcutaneous administration of liposomes: A comparison with the intravenous and intraperitoneal routes of injection
6. Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes
7. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
8. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells
9. Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop
10. Selective HIV-1-induced downmodulation of CD4 and coreceptors
11. AIDS-related Kaposi's sarcoma: A phase II study of liposomal doxorubicin
12. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
13. Fusogenic determinants of highly cytopathic subtype D Zairian isolate HIV-1 NDK
14. Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2′,3′-dideoxyinosine
15. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics
16. Multi-branched peptides based on the HIV-1 V3 loop consensus motif inhibit HIV-1 and HIV-2 infection in CD4+ and CD4- cells
17. V3 loop-derived multibranched peptides as inhibitors of HIV infection in CD4+ and CD4- cells
18. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma
19. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin
20. Lymphoid tissues targeting of liposome-encapsulated 2′,3′-dideoxyinosine
21. Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2′,3′-dideoxyinosine
22. Liposome pharmacokinetics
23. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1
24. Delivery of cytokines by liposomes: Hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes
25. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro
26. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant
27. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system
28. Trends and developments in liposome drug delivery systems
29. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes
30. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide-cells by LAV-2/B
31. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120
32. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody
33. Neutralization of HIV-1: A paradox of humoral proportions
34. A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma
35. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin
36. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. Influence of liposomal size, lipid composition and lipid dose
37. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides
38. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
39. Liposomal encapsulation of 3′-azido-3′-deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS-induced immunosuppression
40. Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689 502, an inhibitor of the viral protease
41. SPC3, a non toxic peptide inhibitor of HIV infection
42. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes
43. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene
44. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes
45. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages
46. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms
47. Effect of cholesterol on molecular transport of organic cations across liposome bilayers probed by second harmonic generation